

FROM :

PHONE NO. :

Nov. 30 2004 01:47AM P1

Continuation Sheet (PTOL-324)

Application No. 10/688,757

Continuation of 4(e) Other: Status identifiers should be present after each claim number. Markings and/or underlining were not presented with amended claims.

# **Notice of Non-Compliant Amendment (37 CFR 1.121)**

Application No.

10/688,757

Applicant(s)

CHANG ET AL.

Examiner

Art Unit

Timothy Cole

1700

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

The amendment document filed on **25 November 2005** is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- ☒ 1. Amendments to the specification:
  - ☒ A. Amended paragraph(s) do not include markings.
  - ☒ B. New paragraph(s) should not be underlined.
  - ☒ C. Other \_\_\_\_\_
- ☐ 2. Abstract:
  - ☐ A. Not presented on a separate sheet. 37 CFR 1.72.
  - ☐ B. Other \_\_\_\_\_
- ☐ 3. Amendments to the drawings:
  - ☐ A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
  - ☐ B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.54 are required.
  - ☐ C. Other \_\_\_\_\_
- ☒ 4. Amendments to the claims:
  - ☒ A. A complete listing of all of the claims is not present.
  - ☒ B. The listing of claims does not include the text of all pending claims (including withdrawn claims).
  - ☒ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
  - ☒ D. The claims of this amendment paper have not been presented in ascending numerical order.
  - ☒ E. Other See Continguation Sheet.

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at <http://www.uspto.gov/web/offices/pao/dapp/opla/procamp/officeflyer.pdf>.

## **TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:**

1. Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted within the time period set forth in the final Office action.
2. Applicant is given one month, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121. If the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a *Quayle* action.

**Extensions of time** are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action.

**Failure to timely respond** to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action; or  
Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.

U.S. Patent and Trademark Office  
PTOL-324 (11-04)

Notice of Non-Compliant Amendment (37 CFR 1.121)

Part of Paper No. 112505

(571)272-0999



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
BUREAU OF PATENTS  
WASHINGTON, DC 20503-1400

APPLICATION NO. 10/688,757	FILING DATE 10/20/2003	FIRST NAMED INVENTOR Yu-An Chang	ATTORNEY DOCKET NO. 7390	CONFIRMATION NO. 1903
INVENTOR Yu-An Chang, Ph.D. 3631 Hamilton Street Irvine, CA 92614		EXAMINER FREDUO, KESUN LI		
		ART UNIT 1713		
		PAPER NUMBER		
DATE MAILED: 12/02/2003				

Please find below and/or attached an Office communication concerning this application or proceeding.

femorofemoral artery implant, femoral-popliteal artery implant, femoro-ubial artery implant, fibular artery implant, plantar artery implant, dorsalis-pedis artery implant, arterial-venous fistulae, and venous implant, etc.

7. (Currently Amended) The drugs of claim 6 can be anti-coagulant drugs, anti-cancer drugs, Vascular Endothelial Growth Factor (VEGF) and/or Platelet Derived Growth Factor (PDGF) which include, but not limited to heparin, Taxol, and wherein said angiogenesis factor is selected from the group consisting of VEGF, VEGF 2, bFGF, VEGF121, VEGF163, VEGF189, VEGF206, PDGF, PDGF, TGF- $\beta$ , PDGF, PDWHP, etc.

8. (Currently Amended) The bio-compatible surface processed copolymers can covalently attached with cells from specific tissue or cell lines to create special biological effects, such as endothelial cells to reduce blood activation, and other unwanted or harmful biological activities.